睿知中国医院研究地图
候选清单

正在招募肺癌未注明分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Adjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLC

ClinicalTrials.gov 上登记的一项肺癌开放试验,由华中科技大学同济医学院附属同济医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07837739,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically confirmed primary non-small cell lung cancer, pathologic stage IA2 to IIB; protocol summary further specifies lung adenocarcinoma / predominantly non-squamous histology.

    入选标准第 2 条

    EGFR mutation-positive disease confirmed by the central laboratory, including exon 19 deletion, L858R, exon 20 insertion, or PACC mutation.

    入选标准第 4 条

  3. For stage IA2 disease, at least one protocol-defined high-risk feature: invasive component >2 cm; lymphovascular invasion; high-grade pattern comprising ≥20% solid, micropapillary, cribriform, or complex glandular components; spread through air spaces (STAS); or sublobar resection (segmentectomy/wedge resection).

    入选标准第 3 条

  4. ECOG Performance Status 0-1.

    入选标准第 7 条

  5. Hematologic criteria: RBC ≥3.0×10\^12/L; WBC ≥3.5×10\^9/L; ANC ≥1.5×10\^9/L; platelet count ≥100×10\^9/L; hemoglobin ≥90 g/L.

    入选标准第 8 条

    Renal function: serum creatinine ≤1.2×ULN.

    入选标准第 9 条

    Hepatic function: total bilirubin ≤1.5×ULN; ALT and AST ≤1.5×ULN.

    入选标准第 10 条

  6. Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the study.

    入选标准第 13 条

    Pregnancy or breastfeeding.

    排除标准第 3 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:既往治疗;影像与可测量病灶;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07837739,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age 18-75 years, male or female, with written informed consent.
  2. Histologically confirmed primary non-small cell lung cancer, pathologic stage IA2 to IIB; protocol summary further specifies lung adenocarcinoma / predominantly non-squamous histology.
  3. For stage IA2 disease, at least one protocol-defined high-risk feature: invasive component >2 cm; lymphovascular invasion; high-grade pattern comprising ≥20% solid, micropapillary, cribriform, or complex glandular components; spread through air spaces (STAS); or sublobar resection (segmentectomy/wedge resection).
  4. EGFR mutation-positive disease confirmed by the central laboratory, including exon 19 deletion, L858R, exon 20 insertion, or PACC mutation.
  5. Complete surgical resection with negative margins (R0); lobectomy or sublobar resection may be included according to the protocol.
  6. No previous antitumor treatment, including no neoadjuvant radiotherapy, chemotherapy, targeted therapy, or immunotherapy.
  7. ECOG Performance Status 0-1.
  8. Hematologic criteria: RBC ≥3.0×10\^12/L; WBC ≥3.5×10\^9/L; ANC ≥1.5×10\^9/L; platelet count ≥100×10\^9/L; hemoglobin ≥90 g/L.
  9. Renal function: serum creatinine ≤1.2×ULN.
  10. Hepatic function: total bilirubin ≤1.5×ULN; ALT and AST ≤1.5×ULN.
  11. Able and willing to comply with protocol-specified treatment/observation and follow-up.
  12. Adequate tumor tissue available and willingness to provide tissue and blood samples for study analyses.
  13. Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the study.

排除标准:Exclusion Criteria:

  1. Contraindication to anesthesia or surgery, or death attributable to the surgical procedure before study enrollment/evaluation.
  2. Any systemic disease incompatible with participation in the clinical study or inability to provide written informed consent.
  3. Pregnancy or breastfeeding.
  4. Known active alcohol or drug abuse or dependence.
  5. Any serious or unstable medical condition or psychiatric disorder that, in the investigator's judgment, would make participation inappropriate.
  6. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.

引自 ClinicalTrials.gov, NCT07837739, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07837739,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07837739